MANGOCEUTICALS, INC. Files 8-K Report

Ticker: MGRX · Form: 8-K · Filed: Feb 12, 2025 · CIK: 1938046

Mangoceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyMangoceuticals, INC. (MGRX)
Form Type8-K
Filed DateFeb 12, 2025
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: filing, sec, corporate-event

TL;DR

MANGOCEUTICALS, INC. filed an 8-K, likely with updates. Check for details.

AI Summary

On February 12, 2025, MANGOCEUTICALS, INC. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or material events beyond the filing itself were detailed in the provided text.

Why It Matters

This 8-K filing indicates that MANGOCEUTICALS, INC. is providing updates or submitting required documentation to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific financial or operational details that would indicate high risk.

Key Players & Entities

FAQ

What specific "Other Events" are reported in this 8-K filing?

The provided text does not specify the details of the "Other Events" reported in the 8-K filing.

What is the purpose of filing an 8-K report?

An 8-K report is filed to announce major corporate events that shareholders should know about, such as acquisitions, bankruptcy, or changes in management.

When was this 8-K report filed?

This 8-K report was filed on February 12, 2025.

What is MANGOCEUTICALS, INC.'s state of incorporation?

MANGOCEUTICALS, INC. is incorporated in Texas.

What are the principal executive offices of MANGOCEUTICALS, INC.?

The principal executive offices of MANGOCEUTICALS, INC. are located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248.

Filing Stats: 852 words · 3 min read · ~3 pages · Grade level 12.2 · Accepted 2025-02-12 08:00:12

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: February 12, 2025 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing